p38 MAPK in cardioprotection - are we there yet?

Area of Science:

• Biochemistry
• Cellular Biology
• Pharmacology

Background:

• Protein kinases (PKs) regulate essential cellular processes by phosphorylating substrate proteins.
• Stress-activated kinases, like the p38 MAPK family, respond to cellular stresses but can contribute to disease pathology.
• Dysregulation of p38 signaling is implicated in cardiovascular diseases, similar to other signaling pathways where inhibition is beneficial.

Purpose of the Study:

• To review the structure, function, and history of p38 inhibitors.
• To examine the use of p38 inhibitors in preclinical studies.
• To summarize recent cardiovascular clinical trial results for p38 inhibitors.

Main Methods:

• Literature review of p38 kinase structure and function.
• Analysis of preclinical studies involving p38 inhibitors.
• Synthesis of data from recent cardiovascular clinical trials.

Main Results:

• p38 MAPKs are involved in cellular adaptation to stress but can mediate maladaptive responses in disease.
• Preclinical studies have explored p38 inhibitors for various conditions.
• Recent clinical trials in cardiovascular diseases are summarized to assess therapeutic potential.

Conclusions:

• p38 signaling pathways, while crucial for survival, can exacerbate cardiovascular diseases.
• Inhibition of p38 may offer therapeutic benefits in cardiovascular and other disease states.
• Further clinical evaluation is needed to determine the efficacy and safety of p38 inhibitors.